Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Dose-parallel-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-1139 Injection in Patients With Plaque Psoriasis Who Have Poor Response to Biological Agents

NCT07758075 is registered in ClinicalTrials.gov with Guangdong Hengrui Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT07758075
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07758075 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Dose-parallel-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-1139 Injection in Patients With Plaque Psoriasis Who Have Poor Response to Biological Agents
Lead sponsor
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase
Phase 2
Overall status
Not yet recruiting
Start date
August 31, 2026
Completion date
May 31, 2028
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis